Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way. Moreover, she highlights the importance of achieving reimbursement for three key products for Multiple Sclerosis and Oncology as well as the leading role Sanofi Genzyme plays, as the global pioneer in orphan drugs, in driving forward rare disease awareness within the medical community and throughout the Polish population.
What have been the key milestones in the last two years that stand out for Sanofi Genzyme Poland?
"We will be constantly involved in rising awareness about diseases underlying that early treatment is beneficial for patients and for the system."
